I-Flow Corporation Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • I-Flow Corporation's estimated annual revenue is currently $1.3B per year.(i)
  • I-Flow Corporation's estimated revenue per employee is $251,000

Employee Data

  • I-Flow Corporation has 5014 Employees.(i)
  • I-Flow Corporation grew their employee count by -1% last year.

I-Flow Corporation's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is I-Flow Corporation?

I-Flow Corporation (I-Flow) is engaged in designing, developing and marketing drug delivery systems and surgical products for post-surgical pain relief and surgical site care. The Company’s products are used in hospitals, free-standing surgery centers, homes and other settings. The Company’s flagship product line, ON-Q Pain Relief System (ON-Q), reduces the need for narcotics to relieve pain after surgery so patients get home faster. I-Flow manufactures and sells the ON-Q line of compact, portable infusion pumps, catheters and pain kits that automatically administer local anesthetic directly to or near the surgical site or near an adjacent nerve or nerve bundle. The Company also manufactures and sells a line of disposable infusion pumps used to administer chemotherapies, antibiotics and other medications. On February 15, 2008, the Company acquired AcryMed Incorporated (AcryMed). (Source: 10-K)

keywords:N/A

N/A

Total Funding

5014

Number of Employees

$1.3B

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

I-Flow Corporation News

2022-04-20 - How to move your headquarters to the metaverse

I'm not moving my company to the metaverse to be cool—I'm doing it because ... I know that's why many corporate chiefs are desperate to get...

2022-04-20 - Continue To Avoid Redfin Corporation

In some sense they're infinitely more expensive now, given the absence of free cash flow. As I noted above, the company has never generated...

2007-12-14 - Life sciences briefing: Friday, Dec. 14, 2007

TODAY’S HEADLINES: AcryMed, wound-healing specialist, sells itself to I-Flow for $25M (release) Stent maker Devax pulls $85M IPO filing (Edgar) Cempra Pharma gets $10M for anti-infective drugs (TechJournal South) Genesis Genomics takes in C$312K for DNA-based diagnostics (GenomeWeb) AcryMed ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1634.6M51214%N/A
#2
$4540M5720-7%$181.9M
#3
$7400M61263%N/A
#4
N/A6167N/AN/A
#5
$1303.7M64863%N/A